Found: 62
Select item for more details and to access through your institution.
Targeted therapies for metastatic esophagogastric cancer.
- Published in:
- 2011
- By:
- Publication type:
- journal article
A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Circulating Tumor Cells Predict Occult Metastatic Disease and Prognosis in Pancreatic Cancer.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2018, v. 25, n. 4, p. 1000, doi. 10.1245/s10434-017-6290-8
- By:
- Publication type:
- Article
Value of Primary Tumor Gene Signatures in Colon Cancer When National Quality Standards are Adhered to: Preliminary Results of an International Prospective Multicenter Trial.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2015, v. 22, n. 2, p. 535, doi. 10.1245/s10434-014-4013-y
- By:
- Publication type:
- Article
Impact of Tumor Grade on Pancreatic Cancer Prognosis: Validation of a Novel TNMG Staging System.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2013, v. 20, n. 13, p. 4322, doi. 10.1245/s10434-013-3159-3
- By:
- Publication type:
- Article
Time-Dependent Trends in Lymph Node Yield and Impact on Adjuvant Therapy Decisions in Colon Cancer Surgery: An International Multi-Institutional Study.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2012, v. 19, n. 13, p. 4178, doi. 10.1245/s10434-012-2501-5
- By:
- Publication type:
- Article
Impact of Tumor Grade on Prognosis in Pancreatic Cancer: Should We Include Grade in AJCC Staging?
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2010, v. 17, n. 9, p. 2312, doi. 10.1245/s10434-010-1071-7
- By:
- Publication type:
- Article
Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance.
- Published in:
- Nature Medicine, 2010, v. 16, n. 12, p. 1414, doi. 10.1038/nm.2236
- By:
- Publication type:
- Article
Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC).
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 1, p. 182, doi. 10.1007/s10637-020-01000-6
- By:
- Publication type:
- Article
Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.
- Published in:
- PLoS ONE, 2013, v. 8, n. 3, p. 1, doi. 10.1371/journal.pone.0054014
- By:
- Publication type:
- Article
Starting at the Front Line in Metastatic Pancreatic Cancers: As New Options Emerge, How Do You Select and Sequence?
- Published in:
- Oncology (08909091), 2024, v. 38, n. 9, p. 352
- By:
- Publication type:
- Article
Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment.
- Published in:
- British Journal of Clinical Pharmacology, 2022, v. 88, n. 7, p. 3392, doi. 10.1111/bcp.15294
- By:
- Publication type:
- Article
Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Metastatic Pancreatic Cancer.
- Published in:
- Cancers, 2024, v. 16, n. 7, p. 1323, doi. 10.3390/cancers16071323
- By:
- Publication type:
- Article
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
How Quality of Life Can Inform Management Decisions in Later-Line Metastatic Colorectal Cancer.
- Published in:
- Clinical Advances in Hematology & Oncology, 2021, v. 19, p. 1
- By:
- Publication type:
- Article
Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 3, p. 510, doi. 10.1007/s10637-013-0062-5
- By:
- Publication type:
- Article
A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 3, p. 518, doi. 10.1007/s10637-014-0064-y
- By:
- Publication type:
- Article
Erratum to: Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.
- Published in:
- 2014
- By:
- Publication type:
- Erratum
Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1.
- Published in:
- Advanced Science, 2021, v. 8, n. 6, p. 1, doi. 10.1002/advs.202002147
- By:
- Publication type:
- Article
Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1.
- Published in:
- Advanced Science, 2021, v. 8, n. 6, p. 1, doi. 10.1002/advs.202002147
- By:
- Publication type:
- Article
Bilateral Subfoveal Neurosensory Retinal Detachment Associated With MEK Inhibitor Use for Metastatic Cancer.
- Published in:
- JAMA Ophthalmology, 2014, v. 132, n. 8, p. 1005, doi. 10.1001/jamaophthalmol.2014.976
- By:
- Publication type:
- Article
Monoclonal antibodies that target fibroblast growth factor receptor 2 isoform b and Claudin‐18 isoform 2 splicing variants in gastric cancer and other solid tumours.
- Published in:
- Clinical & Translational Medicine, 2024, v. 14, n. 6, p. 1, doi. 10.1002/ctm2.1736
- By:
- Publication type:
- Article
CMET-04. METASTATIC GASTROINTESTINAL CANCER TO THE SKULL BASE MIMICKING NF2.
- Published in:
- Neuro-Oncology, 2018, v. 20, p. vi54, doi. 10.1093/neuonc/noy148.217
- By:
- Publication type:
- Article
Safety Considerations of Cancer Nanomedicine—A Key Step toward Translation.
- Published in:
- Small, 2020, v. 16, n. 36, p. 1, doi. 10.1002/smll.202000673
- By:
- Publication type:
- Article
Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Ramucirumab plus FOLFIRI or irinotecan as second-line treatment for patients with gastroesophageal adenocarcinoma: a review and meta-analysis of an emerging option.
- Published in:
- Frontiers in Oncology, 2024, p. 01, doi. 10.3389/fonc.2024.1419338
- By:
- Publication type:
- Article
Exploratory Analysis of Patients With Gastric/Gastroesophageal Junction Adenocarcinoma With or Without Liver Metastasis From the Phase 3 RAINBOW Study.
- Published in:
- Journal of Gastric Cancer, 2023, v. 23, n. 2, p. 289, doi. 10.5230/jgc.2023.23.e15
- By:
- Publication type:
- Article
Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial.
- Published in:
- British Journal of Cancer, 2019, v. 121, n. 4, p. 318, doi. 10.1038/s41416-019-0517-3
- By:
- Publication type:
- Article
Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial.
- Published in:
- 2019
- By:
- Publication type:
- journal article
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Axitinib or Bevacizumab Plus FOLFIRI or Modified FOLFOX-6 After Failure of First-Line Therapy for Metastatic Colorectal Cancer: A Randomized Phase II Study.
- Published in:
- Clinical Colorectal Cancer, 2013, v. 12, n. 4, p. 239, doi. 10.1016/j.clcc.2013.09.001
- By:
- Publication type:
- Article
<sup>18</sup>F-FDG PET/CT imaging biomarkers for early and late evaluation of response to first-line chemotherapy in patients with pancreatic ductal adenocarcinoma.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.261952
- By:
- Publication type:
- Article
<sup>18</sup>F-FDG PET/CT imaging biomarkers for early and late evaluation of response to first-line chemotherapy in patients with pancreatic ductal adenocarcinoma.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.261952
- By:
- Publication type:
- Article
<sup>18</sup>F-FDG PET/CT imaging biomarkers for early and late evaluation of response to first-line chemotherapy in patients with pancreatic ductal adenocarcinoma.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.261952
- By:
- Publication type:
- Article
<sup>18</sup>F-FDG PET/CT imaging biomarkers for early and late evaluation of response to first-line chemotherapy in patients with pancreatic ductal adenocarcinoma.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.261952
- By:
- Publication type:
- Article
<sup>18</sup>F-FDG PET/CT imaging biomarkers for early and late evaluation of response to first-line chemotherapy in patients with pancreatic ductal adenocarcinoma.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.121.261952
- By:
- Publication type:
- Article
<sup>18</sup>F-FDG PET/CT imaging biomarkers for early and late evaluation of response to first-line chemotherapy in patients with pancreatic ductal adenocarcinoma.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.121.261952
- By:
- Publication type:
- Article
Poorly differentiated histologic grade correlates with worse survival in SMAD4 negative pancreatic adenocarcinoma patients.
- Published in:
- Journal of Surgical Oncology, 2021, v. 123, n. 2, p. 389, doi. 10.1002/jso.26279
- By:
- Publication type:
- Article
Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2015, v. 76, n. 1, p. 61, doi. 10.1007/s00280-015-2744-5
- By:
- Publication type:
- Article
Keeping immune checkpoint inhibitor myocarditis in check: advanced circulatory mechanical support as a bridge to recovery.
- Published in:
- ESC Heart Failure, 2021, v. 8, n. 5, p. 4301, doi. 10.1002/ehf2.13545
- By:
- Publication type:
- Article
Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure–safety analyses in patients with metastatic pancreatic cancer.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2021, v. 10, n. 12, p. 1550, doi. 10.1002/psp4.12725
- By:
- Publication type:
- Article
Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
- Published in:
- 2023
- By:
- Publication type:
- journal article
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial.
- Published in:
- Gastric Cancer, 2024, v. 27, n. 3, p. 558, doi. 10.1007/s10120-024-01466-w
- By:
- Publication type:
- Article
Correction to: Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061.
- Published in:
- Gastric Cancer, 2021, v. 24, n. 6, p. 1330, doi. 10.1007/s10120-021-01200-w
- By:
- Publication type:
- Article
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.
- Published in:
- Gastric Cancer, 2019, v. 22, n. 4, p. 828, doi. 10.1007/s10120-018-00909-5
- By:
- Publication type:
- Article
Role of PD-1 Inhibitors in the Treatment of Esophagogastric Adenocarcinoma: Patient Selection and Reported Outcomes.
- Published in:
- Cancer Management & Research, 2023, v. 15, p. 265, doi. 10.2147/CMAR.S341468
- By:
- Publication type:
- Article
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice